ClinVar Miner

Submissions for variant NM_000179.3(MSH6):c.1691C>A (p.Ser564Ter)

dbSNP: rs864622153
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV000204908 SCV000259478 pathogenic Hereditary nonpolyposis colorectal neoplasms 2023-02-28 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Ser564*) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Lynch syndrome (PMID: 27601186). ClinVar contains an entry for this variant (Variation ID: 219551). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000481005 SCV000570637 pathogenic not provided 2017-04-14 criteria provided, single submitter clinical testing This variant is denoted MSH6 c.1691C>A at the cDNA level and p.Ser564Ter (S564X) at the protein level. The substitution creates a nonsense variant, which changes a Serine to a premature stop codon (TCA>TAA), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This variant has been observed in an individual tested on a hereditary colorectal cancer panel (Ferber 2016). We consider this variant to be pathogenic.
Ambry Genetics RCV000491176 SCV000580348 pathogenic Hereditary cancer-predisposing syndrome 2024-10-28 criteria provided, single submitter clinical testing The p.S564* pathogenic mutation (also known as c.1691C>A), located in coding exon 4 of the MSH6 gene, results from a C to A substitution at nucleotide position 1691. This changes the amino acid from a serine to a stop codon within coding exon 4. This mutation has been detected in multiple endometrial cancer patients whose tumors demonstrated loss of MSH6 on immunohistochemistry (Ambry internal data). A different nucleotide change at this position (c.1691C>G) that leads to the same stop codon was seen in two Swedish families with Lynch syndrome (Lagerstedt-Robinson K et al. Oncol. Rep., 2016 Nov;36:2823-2835). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Counsyl RCV000576302 SCV000677830 likely pathogenic Lynch syndrome 5 2016-12-12 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000491176 SCV000690217 pathogenic Hereditary cancer-predisposing syndrome 2021-10-01 criteria provided, single submitter clinical testing This variant changes 1 nucleotide in exon 4 of the MSH6 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been observed in an individual affected with ovarian cancer (Color internal data). A different DNA substitution resulting in the same protein consequence (c.1691C>G; p.Ser564*) has been observed in two families affected with Lynch syndrome (PMID: 27601186). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH6 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000481005 SCV000888247 pathogenic not provided 2018-01-16 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV000576302 SCV004018900 pathogenic Lynch syndrome 5 2023-03-28 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation.
PreventionGenetics, part of Exact Sciences RCV004530217 SCV004121047 pathogenic MSH6-related disorder 2022-09-21 criteria provided, single submitter clinical testing The MSH6 c.1691C>A variant is predicted to result in premature protein termination (p.Ser564*). This variant has been reported in an individual being tested on a hereditary colorectal cancer panel (Ferber et al. 2016. Journal of Medical Diagnostic Methods, vol 5). A different nucleotide variant (c.1691C>G) which also causes a premature termination codon at this position has been reported in individuals with Lynch syndrome (Lagerstedt-Robinson et al. 2016. PubMed ID: 27601186). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Nonsense variants in MSH6 are expected to be pathogenic. Given the evidence, we interpret c.1691C>A (p.Ser564*) as pathogenic.
CZECANCA consortium RCV001270947 SCV001451751 pathogenic Breast and/or ovarian cancer 2019-06-11 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.